2018 - Member of Academia Europaea
Elisabeth H. Bel focuses on Asthma, Immunology, Internal medicine, Exhaled nitric oxide and Physical therapy. Her study in Asthma focuses on Anti-asthmatic Agent in particular. The various areas that she examines in her Immunology study include Airway obstruction, Airway, Sputum Cytology and Cohort.
Her Internal medicine research also works with subjects such as
Elisabeth H. Bel spends much of her time researching Asthma, Internal medicine, Immunology, Intensive care medicine and COPD. She has researched Asthma in several fields, including Physical therapy, Disease and Pediatrics. Her work on Mepolizumab, Corticosteroid and Cohort as part of general Internal medicine research is often related to In patient, thus linking different fields of science.
Her Immunology research is multidisciplinary, relying on both Fibrinolysis, Airway and Eosinophilic. Her studies deal with areas such as Pulmonary disease, Severity of illness and Respiratory system as well as Intensive care medicine. Elisabeth H. Bel interconnects Observational study and Asthma Control Questionnaire in the investigation of issues within COPD.
Her scientific interests lie mostly in Asthma, Internal medicine, Mepolizumab, Severe asthma and COPD. Her Asthma research entails a greater understanding of Immunology. Her Internal medicine study deals with Gastroenterology intersecting with Nasal polyps, Exhaled nitric oxide and Peripheral blood.
In her work, Long term safety is strongly intertwined with Eosinophilic asthma, which is a subfield of Mepolizumab. She combines subjects such as Airway inflammation, Clinical research, Randomized controlled trial and Asthma Control Questionnaire with her study of Severe asthma. Her research in the fields of Obstructive lung disease overlaps with other disciplines such as Novelty.
Elisabeth H. Bel spends much of her time researching Asthma, Internal medicine, Immunology, Intensive care medicine and Exacerbation. She studies Exhaled nitric oxide which is a part of Asthma. Her research links Gastroenterology with Internal medicine.
Her research investigates the connection with Intensive care medicine and areas like COPD which intersect with concerns in Disease burden. As a part of the same scientific study, she usually deals with the Exacerbation, concentrating on Emergency department and frequently concerns with Single-nucleotide polymorphism. In her study, Prednisone is strongly linked to Placebo, which falls under the umbrella field of Benralizumab.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs
J. Bousquet;H. J. Schünemann;B. Samolinski;P. Demoly.
The Journal of Allergy and Clinical Immunology (2012)
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung;Sally E. Wenzel;Jan L. Brozek;Andrew Bush.
European Respiratory Journal (2014)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel;Sally E. Wenzel;Philip J. Thompson;Charlene M. Prazma.
The New England Journal of Medicine (2014)
After asthma: redefining airways diseases
Ian D Pavord;Richard Beasley;Alvar Agusti;Gary P Anderson.
The Lancet (2017)
Treatable traits: toward precision medicine of chronic airway diseases.
Alvar Agusti;Elisabeth Bel;Mike Thomas;Claus Vogelmeier.
European Respiratory Journal (2016)
Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma.
David Cheung;Mieke C. Timmers;Aeilko H. Zwinderman;Elisabeth H. Bel.
The New England Journal of Medicine (1992)
The prevalence of severe refractory asthma
Pieter-Paul W. Hekking;Reinier R. Wener;Marijke Amelink;Aelko H. Zwinderman.
The Journal of Allergy and Clinical Immunology (2015)
Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society
KF Chung;P Godard;E Adelroth;J Ayres.
European Respiratory Journal (1999)
Risk factors of frequent exacerbations in difficult-to-treat asthma
ten A. Brinke;P.J. Sterk;A.A.M. Masclee;Ph. Spinhoven.
European Respiratory Journal (2005)
An electronic nose in the discrimination of patients with asthma and controls
Silvano Dragonieri;Robert Schot;Bart J.A. Mertens;Saskia Le Cessie.
The Journal of Allergy and Clinical Immunology (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: